122 related articles for article (PubMed ID: 34637629)
1. Optimal Inhalation Flow Pattern from Turbuhaler Predicted by Laser Photometry.
Kondo T; Hibino M; Tanigaki T; Tajiri S; Horiuchi S
J Aerosol Med Pulm Drug Deliv; 2022 Jun; 35(3):139-145. PubMed ID: 34637629
[No Abstract] [Full Text] [Related]
2. [CHARACTERISTICS OF BUDEFORU
Kondo T; Tanigaki T; Hibino M; Tajiri S; Horiuchi S; Ohbayashi H
Arerugi; 2022; 71(1):37-41. PubMed ID: 35173123
[TBL] [Abstract][Full Text] [Related]
3. Real life dose emission characterization using COPD patient inhalation profiles when they inhaled using a fixed dose combination (FDC) of the medium strength Symbicort
Bagherisadeghi G; Larhrib EH; Chrystyn H
Int J Pharm; 2017 Apr; 522(1-2):137-146. PubMed ID: 28254655
[TBL] [Abstract][Full Text] [Related]
4. Correcting Photo Reflection Method Output and Its Application in the Dynamic Analysis of Particle Release from Dry Powder Inhalers.
Kondo T; Hibino M; Tanigaki T; Tajiri S; Horiuchi S
J Aerosol Med Pulm Drug Deliv; 2021 Aug; 34(4):223-230. PubMed ID: 33147100
[No Abstract] [Full Text] [Related]
5. Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a Spiromax® dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease.
Bagherisadeghi G; Chrystyn H; Abadelah M; Larhrib EH
Eur J Pharm Sci; 2019 Nov; 139():105059. PubMed ID: 31472254
[TBL] [Abstract][Full Text] [Related]
6. Budesonide + formoterol delivered via Spiromax
Lewis A; Torvinen S; Dekhuijzen PNR; Chrystyn H; Melani A; Zöllner Y; Kolbe K; Watson AT; Blackney M; Plich A
Respir Med; 2017 Aug; 129():179-188. PubMed ID: 28732829
[TBL] [Abstract][Full Text] [Related]
7. InVitro Evaluation of Optimal Inhalation Flow Patterns for Commercial Dry Powder Inhalers and Pressurized Metered Dose Inhalers With Human Inhalation Flow Pattern Simulator.
Hira D; Okuda T; Mizutani A; Tomida N; Okamoto H
J Pharm Sci; 2018 Jun; 107(6):1731-1735. PubMed ID: 29428382
[TBL] [Abstract][Full Text] [Related]
8. The dry powder inhaler features of the Easyhaler that benefit the management of patients.
Chrystyn H; Lavorini F
Expert Rev Respir Med; 2020 Apr; 14(4):345-351. PubMed ID: 32013627
[No Abstract] [Full Text] [Related]
9. Onset of action of budesonide/formoterol Spiromax(®) compared with budesonide/formoterol Turbuhaler(®) in patients with COPD.
Cazzola M; Ora J; Di Paolo A; Puxeddu E; Calzetta L; Rogliani P
Pulm Pharmacol Ther; 2016 Aug; 39():48-53. PubMed ID: 27344046
[TBL] [Abstract][Full Text] [Related]
10. Analysis of Drug Release Dynamics of the Reservoir-type Dry Powder Inhalers.
Tajiri S; Kondo T; Tanigaki T; Asano K; Hibino M; Horiuchi S; Kobayashi I; Nishiya K
Tokai J Exp Clin Med; 2020 Sep; 45(3):102-107. PubMed ID: 32901895
[TBL] [Abstract][Full Text] [Related]
11. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler.
Chrystyn H; Safioti G; Keegstra JR; Gopalan G
Int J Pharm; 2015 Aug; 491(1-2):268-76. PubMed ID: 26043823
[TBL] [Abstract][Full Text] [Related]
12. Daily inhaled flow profiles and drug release from dry powder inhalers in patients with bronchial asthma.
Tajiri S; Kondo T; Tanigaki T; Hibino M; Asano K
Respir Med; 2022 Sep; 201():106950. PubMed ID: 35963030
[TBL] [Abstract][Full Text] [Related]
13. Effect of Flow Rate on In Vitro Aerodynamic Performance of NEXThaler(®) in Comparison with Diskus(®) and Turbohaler(®) Dry Powder Inhalers.
Buttini F; Brambilla G; Copelli D; Sisti V; Balducci AG; Bettini R; Pasquali I
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):167-78. PubMed ID: 26355743
[TBL] [Abstract][Full Text] [Related]
14. Impact of holding position during inhalation on drug release from a reservoir-, blister- and capsule-type dry powder inhaler.
Kondo T; Tanigaki T; Yokoyama H; Hibino M; Tajiri S; Akazawa K; Yamada Y; Cassan SM
J Asthma; 2017 Oct; 54(8):792-797. PubMed ID: 27929704
[TBL] [Abstract][Full Text] [Related]
15. Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study.
Janson C; Lööf T; Telg G; Stratelis G; Nilsson F
NPJ Prim Care Respir Med; 2016 Nov; 26():16053. PubMed ID: 27853177
[TBL] [Abstract][Full Text] [Related]
16. Numerical simulation of emitted particle characteristics and airway deposition distribution of Symbicort(®) Turbuhaler(®) dry powder fixed combination aerosol drug.
Farkas Á; Jókay Á; Balásházy I; Füri P; Müller V; Tomisa G; Horváth A
Eur J Pharm Sci; 2016 Oct; 93():371-9. PubMed ID: 27552906
[TBL] [Abstract][Full Text] [Related]
17. Inhalation characteristics of asthma patients, COPD patients and healthy volunteers with the Spiromax® and Turbuhaler® devices: a randomised, cross-over study.
Azouz W; Chetcuti P; Hosker H; Saralaya D; Chrystyn H
BMC Pulm Med; 2015 May; 15():47. PubMed ID: 25927483
[TBL] [Abstract][Full Text] [Related]
18. Clinical equivalence of budesonide dry powder inhaler and pressurized metered dose inhaler.
Srichana T; Juthong S; Thawithong E; Supaiboonpipat S; Soorapan S
Clin Respir J; 2016 Jan; 10(1):74-82. PubMed ID: 25043636
[TBL] [Abstract][Full Text] [Related]
19. [IS IT NECESSARY TO PROHIBIT SIDE-HOLE CLOSURE IN USE OF THE DRY POWDER INHALERS?].
Kondo T; Tanigaki T; Hibino M; Tajiri S; Horiuchi S; Fukuda M; Ohbayashi H
Arerugi; 2019; 68(2):96-100. PubMed ID: 30867367
[TBL] [Abstract][Full Text] [Related]
20. The inhalation characteristics of patients when they use different dry powder inhalers.
Azouz W; Chetcuti P; Hosker HS; Saralaya D; Stephenson J; Chrystyn H
J Aerosol Med Pulm Drug Deliv; 2015 Feb; 28(1):35-42. PubMed ID: 24815999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
